[Review] At the end of November 2009, the Ministry of Human Resources and Social Security published the latest version of the national medical insurance drug catalog. Before and after this, the medicines in various catalogues began to increase prices quietly. The highest prices for medicines rose by 82%, and the prices of some generic drugs even exceeded imports. medicine.
Last year, the price was 93.5 yuan for medicines, and now the price was raised to 170 yuan; last year's price was 1,082 yuan, and now it was sold for 1,580 yuan. During a new round of drug bidding and procurement in various regions, the reporter discovered that some new countries have entered the country. Medicare drug prices began to quietly increase prices.
From the information currently available to reporters, there are already more than 30 varieties of medicines, and prices have risen in varying degrees. From the perspective of the price rise of these drugs, most of them focus on the new version of the National Health Insurance Directory.
What are the reasons for the increase in the prices of drugs entering the health insurance catalog? Does this price increase mean that there are loopholes in the drug pricing mechanism?
Drug companies have raised their prices before and after the medical insurance list is published
On the last day of November 2009, the Ministry of Human Resources and Social Security announced the new "National Basic Medical Insurance, Industrial Injury Insurance and Maternity Insurance Drug List". Compared to the 2004 version of the catalog, the new catalog adds 260 drugs.
For pharmaceutical manufacturers, this document, referred to simply as the Medicare Catalog, affects the development of the company to a certain extent. It is a golden sign for the company to expand its market, because if it enters the Medicare Catalog, it means that the company’s products will receive a lot of products. Stable orders also mean that the company's costs will be diluted and prices will have room to fall.
Interestingly, just four days before the release of the new national medical insurance catalog, a Shenzhen Pharmaceutical Co., Ltd. made a price adjustment filing at the Shandong Provincial Price Bureau, adjusting the price of its 20mg unit of aerobbicin freeze-dried powder injection to Supporting 121 yuan, according to the Price Bureau's documents, the new price will begin on November 30. Prior to this, the price of this product was 113 yuan.
On November 30, the National Health Insurance Catalogue announced that 20mg of azarubin lyophilized powder was listed.
For the implementation of the new price five days earlier than Aarubicin, there is also a new drug in the National Health Insurance Directory. According to the Liaofafa (2009) No. 111 document, a drug produced by a local company called Elemene Oral Milk raised the price on November 25.
Elemene is a medicine for the treatment of tumors. The elemene oral milk produced by the above company was approved by the State Food and Drug Administration in September 2002. Before entering the National Health Insurance Catalog, Elemene Oral Milk entered the Liaoning Medical Insurance Catalogue.
From the document point of view, a new price of 20ml: 200mg of Elemene oral milk is 170 yuan, but before the price increase, the same specification of Elemene oral milk price is only 93.5 yuan per one. In other words, the price of the medicine that is about to enter the National Health Insurance List rose by 82% five days before the release of the National Health Insurance Catalogue.
Digital IZOD Impact Test Machine
Digital Izod Impact Test Machine,Digital Charpy Izod Impact Tester,Digital Izod Impact Testing Machine,Plastic Impact Testing Machines
Dongguan Best Instrument Technology Co., Ltd , https://www.dgbestinstrument.com